Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection - Peng, Ning; Mao, Lin-Feng; Su, Jia-Yong; Liu, Shao-Ping; Ou, Jun-Jie; Chen, Shu-Chang; Su, Ze; Li, Wen-Feng; Yang, Fu-Quan; Zhou, Yong-Heng; Li, Le; Zhong, Jian-Hong (Frontiers in Immunology, 2025)